医学
伊克泽珠单抗
塞库金单抗
依那西普
英夫利昔单抗
阿达木单抗
临床试验
银屑病
加药
随机对照试验
皮肤病科
乌斯特基努马
生物仿制药
重症监护医学
内科学
银屑病性关节炎
肿瘤坏死因子α
作者
Charlie Yue Wang,Peter Foley,Chris I. Baker,Marius Rademaker
出处
期刊:PubMed
日期:2021-10-01
卷期号:20 (10): 1063-1071
被引量:1
摘要
While biological treatments for chronic plaque psoriasis should be administered continuously to maximize and maintain efficacy, interruptions in therapy may be necessary for a number of reasons. We reviewed the evidence from clinical trials on efficacy, safety and immunogenicity in clinical trials for approved biologic agents for chronic plaque psoriasis. A systematic search of three major medical databases was performed and a total of 35 articles were included into the analysis, including 13 controlled trials. Trials assessing continuous therapy against dosing as-needed therapy (including infliximab, etanercept and secukinumab) have demonstrated superior efficacy for continuous regimes. However, randomized withdrawal trials for etanercept, adalimumab, ixekizumab, brodalumab, guselkumab, risankizumab and tildrakizumab, showed no significant impact on skin clearance rates in patients who are interrupted once and then re-treated. With the possible exception of infliximab, temporary interruption in biologic therapy appears to be safe and most agents will regain efficacy after re-introduction. J Drugs Dermatol. 2021;20(10):1063-1071. doi:10.36849/JDD.5716.
科研通智能强力驱动
Strongly Powered by AbleSci AI